Table 1.
Immunization and challenge protocol in cynomolgus and rhesus macaquesa.
| Week | Tat proteinb | Ad-Tatc | Ad vector control | Adjuvant control |
|---|---|---|---|---|
| 0 | Tat protein (SC/ID) | Ad-Tat (IN) | AdΔE3 (IN) | Alum (SC) |
| 2 | Tat protein (SC/ID) | Alum (SC) | ||
| 6 | Tat protein (SC/ID) | Alum (SC) | ||
| 11 | Tat protein (SC/ID) | Alum (SC) | ||
| 12 | Ad-Tat (IT) | AdΔE3 (IT) | ||
| 15 | Tat protein (SC/ID) | Alum (SC) | ||
| 21 | Tat protein (SC/ID) | Alum (SC) | ||
| 24 | Tat protein (SC) | Alum (SC) | ||
| 28 | Tat protein (SC/ID) | Alum (SC) | ||
| 32 | Tat protein (SC/ID) | Alum (SC) | ||
| 36 | Tat +ISCOM (IM) | Tat protein (SC) | Alum (SC) | ISCOM (IM) |
| 50 | SHIV89.6P (IV)d | SHIV89.6P (IV) | SHIV89.6P (IV) | SHIV89.6P (IV) |
a
Cynomolgus and rhesus macaques in each immunization group are listed in Fig. 2 and 3, respectively.
b
HIVIIIB Tat protein: 10 μg given subcutaneously (SC) in alum + 6 μg given intradermally (ID) without adjuvant. Last immunization was 16 μg given with ISCOM intramuscularly (IM).
c
Ad-recombinant dose: 5X108 pfu each in PBS administered IN: intranasally; IT: intratracheally.
d
Intravenous (IV) challenge with SHIV89.6Pcyn243,15 MID50, for cynomolgus; SHIV89.6P, 30 MID50, for rhesus.